A Phase 1 interventional study of F230 tablets in Pulmonary Hypertension, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.
Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 19th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 14 of the 35 other live ones, and was the 66th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Xiamen Cardiovascular Hospital, Xiamen University · Sites in China
Ages 18–80
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 136 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 100 across the 47 interventional studies, 750 across the 36 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 85 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Continent Pharmaceutical Co, Ltd., one of the names counted as GNI Group Ltd.. Under that name alone:
Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
GNI Group Ltd. has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension, Pulmonary with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT06023134Jingyi RenClinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure | 2027-09-01 |
| NCT06980584Beijing Chao Yang HospitalStudy on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Hypertension, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification number: 2024LP01242, 2024LP01243). The in vitro activity and in vivo toxicology tests of F230, the lead compound for the treatment of PAH developed by Beijing Contini Pharmaceutical Co., LTD., showed that F230 had the same in vitro activity as the endothelin antagonist on the market. The pharmacodynamics of F230 in rats with nephrogenic hypertension induced by Sunitinib showed that F230 could reduce proteinuria and improve renal index.It is expected to bring higher treatment and survival benefits to the corresponding patients. According to the spirit of NMPA new drug approval, on the basis of the completion of preclinical studies of this drug, the safety, tolerability and pharmacokinetic characteristics of single administration and multiple administration of this drug in healthy volunteers should be investigated first, and the influence of food on the pharmacokinetic characteristics of F230 in humans should be investigated, so as to recommend a safe and effective administration regimen for phase II clinical trials.
This study consists of three parts: the first part is a single administration study (SAD test), the second part is a multiple administration study (MAD test), and the third part is a Food Effect study, which is divided into multiple cohorts according to dose groups and administration regimens.
Single Administration Trial (SAD) : This randomized, double-blind, placebo-controlled, dose-increasing, single-center clinical study was designed to evaluate the safety, tolerability, and pharmacokinetic profile of F230 single administration in healthy volunteers. A total of 78 healthy adult volunteers were planned to be included.This part is expected to develop 6 dose groups: 3mg, 6mg, 12mg, 20mg, 30mg, 40mg, and the groups are indicated by A1-A6. Group A1 planned to include 8 healthy volunteers (stratified by sex, A1:F230 tablets: placebo =3:1), and group A2-A6 planned to include 14 healthy volunteers (stratified by sex, F230 tablets: placebo =6:1), increasing from the initial dose group to the maximum dose group, with each group receiving only a single dose.Qualified volunteers who met the inclusion criteria and did not meet the exclusion criteria were admitted to the phase I laboratory one day before the experiment (D-1) and randomly grouped. The researchers conducted education on the environment, regulations, etc., unified dinner, fasting after 21:00, and did not refrain from drinking water. On the day of administration, F230 tablets or placebo were taken orally on an empty stomach. From the night before the start of the trial to the end of the trial evaluation period (A1:D-1 \~ D3/A2-A6:D-1 \~ D2), the volunteers were kept in the phase I research room. During the study period, safety assessment and PK biological sample collection were conducted according to the protocol. Volunteers completed a safety check on day 3(A1)/ day 2(A2-A2-A6), and were allowed to leave the study center after a comprehensive assessment by the investigator, and then returned to the study center onday 4(A1)/ day 3(A2-A2-A6) or by telephone for safety follow-up.
Multiple dose trial (MAD) : It is initially planned to conduct three dose groups, with preset doses of 10 mg, 20 mg, and 30 mg, Qd, administered for 7 consecutive days. Each group will include 14 volunteers (stratified by gender, F230 tablets: placebo = 6:1), with a total of 42 volunteers planned. All volunteers will stay at the research center from the day before administration (D-1) until 72 hours after the last dose (D10). During the study period, safety assessments and PK biological sample collection will be conducted according to the protocol. On the 10th day of the study (D10, 72 hours after the last dose), the procedures and related safety checks specified in the protocol will be completed. Volunteers may leave the research center only after a comprehensive evaluation by the investigator. Subsequently, volunteers will return to the research center or have a safety follow-up by phone on the 11th day of the study (D11, 96 hours after the last dose).
Research on the Effect of Food on Drugs:
This part is a randomized, open, two-cycle, double-cross clinical study design, referred to as the food impact study. According to the preliminary results of SAD study, it is expected to carry out a dose group: 20mg, and a total of 16 healthy volunteers are planned to be included. The volunteers are randomly divided into K-C and C-K groups by stratified block randomization method, taking gender as a stratified factor, and are randomly divided into two groups at 1:1 ratio, with 8 cases in each group.
Qualified volunteers who met both the inclusion criteria and did not meet any of the exclusion criteria were admitted to the Phase I research room 1 day before the experiment (D-1) and randomly grouped. The researchers conducted education on the environment, regulations, etc., unified dinner, and fasting after 21:00 without drinking water. In the first cycle, K-C group was given fasting, C-K group was given within half an hour after eating a high-fat meal, and group exit examination was conducted on day 2 (D2). After 3 days (72h) of elution, the volunteers underwent a second cycle of dosing on day 6 (D6). In the second cycle, K-C group was administered within half an hour after eating a high-fat meal, and C-K group was administered on an empty stomach. Safety assessment and PK biological sample collection will be conducted during the study in accordance with protocol requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Volunteers must meet all of the following criteria to be selected:
Exclusion Criteria:
Volunteers who meet one of the following conditions are not eligible for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 6 dose groups A1-A6: F230 are initially expected to be developed (A1-A6 test groups were administered 3mg, 6mg, 12mg, 20mg, 30mg, 40mg, respectively). The specific incremental dose can be adjusted according to the test situation. The A1 dose group included 8 volunteers (stratified by sex, F230 tablets: placebo =3:1), and the A2 to A6 dose group included 14 volunteers (stratified by sex, F230 tablets: Placebo =6:1), F230 tablets or placebo were taken orally on an empty stomach on the day of administration. From the night before the start of the trial to the end of the trial evaluation period (A1:D-1 \~ D3/A2-A6:D-1 \~ D2), the volunteers were kept in the phase I research room. During the study period, safety assessment and PK biological sample collection were conducted according to the protocol. The volunteers completed a safety check on day 4(A1)or day3(A2-A6).
Drug: F230 tablets
It is initially planned to conduct three dose groups, with preset doses of 10 mg, 20 mg, and 30 mg, Qd, administered for 7 consecutive days. Each group will include 14 volunteers (stratified by gender, F230 tablets: placebo = 6:1), with a total of 42 volunteers planned. All volunteers will stay at the research center from the day before administration (D-1) until 72 hours after the last dose (D10). During the study period, safety assessments and PK biological sample collection will be conducted according to the protocol. On the 10th day of the study (D10, 72 hours after the last dose), the procedures and related safety checks specified in the protocol will be completed. Volunteers may leave the research center only after a comprehensive evaluation by the investigator. Subsequently, volunteers will return to the research center or have a safety follow-up by phone on the 11th day of the study (D11, 96 hours after the last dose).
Drug: F230 tablets
It is planned to conduct a 20 mg dose group, with an intended enrollment of 16 volunteers. Using gender as a stratification factor, volunteers will be randomly assigned to two dosing sequence groups (K-C group and C-K group). Eight volunteers will receive the drug under fasting conditions in Period 1, while the other eight will consume a high-fat meal first and then receive the drug within 30 minutes in Period 1, with washout on Day 2. After a 3-day (72-hour) washout period, volunteers will proceed to the second dosing period on Day 6. Safety checks will be completed on study Day 7, after which volunteers may leave the research center. A safety follow-up will be conducted on Day 8.
Drug: F230 tablets
SAD: A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg . MAD: B1: F230 tablets 10mg; B2: F230 tablets 20mg; B3: F230 tablets 30mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach.
Single dose:PK parameters: Cmax
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: Tmax
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: AUC0-t
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: AUC0-∞
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: t1/2
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: λz
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: Vz/F
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: CL/F
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: AUC_%Extrap
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: MRT
Blood PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: Ae_u (t1-t2)
Urine PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: Ae_u (0-t)
Urine PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters: Rate_u (max)
Urine PK parameters
Time frame: Within 48 hours of dosing
Single dose:PK parameters:Fe_u (0-t)
Urine PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters:Cmax,ss
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters:Tmax,ss
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: AUC0-τ,ss
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: AUC0-t
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: AUC0-∞
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters:Cmin,ss
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: Cav,ss
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: t1/2
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: λz
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: CLss/F
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: AUC_%Extrap
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: MRT
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: DF
Blood PK parameters
Time frame: Within 48 hours of dosing
Multiple administration: PK parameters: Rac
Blood PK parameters
Time frame: Within 48 hours of dosing
Effects of food on single pharmacokinetic parameters: Cmax
Blood PK parameters
Time frame: Within 48 hours of dosing
Effects of food on single pharmacokinetic parameters: Tmax
Blood PK parameters
Time frame: Within 48 hours of dosing
Effects of food on single pharmacokinetic parameters: AUC
Blood PK parameters
Time frame: Within 48 hours of dosing
Safety and tolerance assessment:Adverse event
Adverse events (AE) are all adverse medical events that occur after a clinical study volunteer receives an investigational drug. It may present as symptoms, signs, disease, or abnormalities in laboratory tests, but may not have a causal relationship with the investigational drug. An AE can be an aggravation of an existing disease, symptoms, signs, laboratory abnormalities, or a newly diagnosed disease, newly occurring symptoms, signs, laboratory outliers, etc.
Time frame: SAD: 3 days
Safety and tolerance assessment:Adverse event
Adverse events (AE) are all adverse medical events that occur after a clinical study volunteer receives an investigational drug. It may present as symptoms, signs, disease, or abnormalities in laboratory tests, but may not have a causal relationship with the investigational drug. An AE can be an aggravation of an existing disease, symptoms, signs, laboratory abnormalities, or a newly diagnosed disease, newly occurring symptoms, signs, laboratory outliers, etc.
Time frame: MAD: 10 days
Safety and tolerance assessment:Adverse event
Adverse events (AE) are all adverse medical events that occur after a clinical study volunteer receives an investigational drug. It may present as symptoms, signs, disease, or abnormalities in laboratory tests, but may not have a causal relationship with the investigational drug. An AE can be an aggravation of an existing disease, symptoms, signs, laboratory abnormalities, or a newly diagnosed disease, newly occurring symptoms, signs, laboratory outliers, etc.
Time frame: Effects of food on drugs test: 7 days
Safety and tolerance assessment:Vital signs measurement:temperature
Measure the axillary temperature, the normal value is 35.9-36.7℃
Time frame: SAD: 3 days;
Safety and tolerance assessment:Vital signs measurement:temperature
Measure the axillary temperature, the normal value is 35.9-36.7℃
Time frame: MAD: 10 days
Safety and tolerance assessment:Vital signs measurement:temperature
Measure the axillary temperature, the normal value is 35.9-36.7℃
Time frame: Effects of food on drugs test: 7 days
Safety and tolerance assessment:Vital signs measurement:breathing
Adult resting breathing rate 12-20 beats per minute
Time frame: SAD: 3 days
Safety and tolerance assessment:Vital signs measurement:breathing
Adult resting breathing rate 12-20 beats per minute
Time frame: MAD: 10 days
Safety and tolerance assessment:Vital signs measurement:breathing
Adult resting breathing rate 12-20 beats per minute
Time frame: Effects of food on drugs test: 7 days
Safety and tolerance assessment:Vital signs measurement:blood pressure
Systolic and diastolic blood pressure were measured
Time frame: SAD: 3 days
Safety and tolerance assessment:Vital signs measurement:blood pressure
Systolic and diastolic blood pressure were measured
Time frame: MAD: 10 days
Safety and tolerance assessment:Vital signs measurement:blood pressure
Systolic and diastolic blood pressure were measured
Time frame: Effects of food on drugs test: 7 days
Safety and tolerance assessment:12-lead ECG test/holter ECG
A 12-lead ECG is a non-invasive test that records the heart's electrical activity through 12 electrodes placed on the body surface. Includes 6 limb leads (Ⅰ, Ⅱ, Ⅲ, aVR, aVL, aVF) and 6 chest leads (V1-V6).A Holter ECG uses a portable device to continuously record heart activity over 24-48 hours, capturing transient abnormalities during daily activities or symptom episodes.It includes PR interval, QRS wave group, QT interval, ST segment,and PP/RR interval.
Time frame: SAD: 3 days
Safety and tolerance assessment:12-lead ECG test/holter ECG
A 12-lead ECG is a non-invasive test that records the heart's electrical activity through 12 electrodes placed on the body surface. Includes 6 limb leads (Ⅰ, Ⅱ, Ⅲ, aVR, aVL, aVF) and 6 chest leads (V1-V6).A Holter ECG uses a portable device to continuously record heart activity over 24-48 hours, capturing transient abnormalities during daily activities or symptom episodes.It includes PR interval, QRS wave group, QT interval, ST segment,and PP/RR interval
Time frame: MAD: 10 days
Safety and tolerance assessment:12-lead ECG test/holter ECG
A 12-lead ECG is a non-invasive test that records the heart's electrical activity through 12 electrodes placed on the body surface. Includes 6 limb leads (Ⅰ, Ⅱ, Ⅲ, aVR, aVL, aVF) and 6 chest leads (V1-V6).A Holter ECG uses a portable device to continuously record heart activity over 24-48 hours, capturing transient abnormalities during daily activities or symptom episodes.It includes PR interval, QRS wave group, QT interval, ST segment,and PP/RR interval.
Time frame: Effects of food on drugs test: 7 days
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.
Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Continent Pharmaceutical Co, Ltd. →